Novel Multi-Ingredient Supplement Facilitates Weight Loss and Improves Body Composition in Overweight and Obese Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Despite the growing recognition of the obesity crisis, its rates continue to rise.

The current first-line therapies, such as dietary changes, energy restriction, and physical activity, are typically met with poor adherence.

Who Took Part

Fifty-five overweight and/or obese participants (age (mean ± SEM): 26 ± 1; body mass index (BMI) (kg/m2): 30.5 ± 0.6) completed this double-blind, placebo-controlled clinical trial.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

The co-primary outcomes were bodyweight and fat mass (kg) changes.

The secondary outcomes included other body composition measures, plasma markers of obesity, fatty liver disease biomarkers, resting energy metabolism, blood pressure, physical performance, and quality of life.

The post-intervention differences between MIS and PLA were examined via ANCOVA which was adjusted for the respective pre-intervention variables.

What Was Measured

The subject headings attached to it are Overweight, Quality of Life, Obesity, Body Composition, Dietary Supplements, MicroRNAs and Antioxidants.

The authors tagged it with the keywords biomarker, catechin, chlorogenic acids, multi-ingredient supplement, nutraceutical and polyphenol.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.